Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

D-penicillamine in systemic sclerosis? Yes!

T A Medsger1, M Lucas, K S Wildy

  • 1Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, PA 15261, USA. medsger@msx.dept-med.pitt.edu

Scandinavian Journal of Rheumatology
|October 2, 2001
PubMed
Summary

D-penicillamine effectively treats diffuse cutaneous systemic sclerosis (dcSSc) skin involvement, even at low doses. Its use is recommended for early dcSSc to favorably alter the disease

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The future fate of Somali upwelling productivity and the implications for fisheries under climate change.

Scientific reports·2026
Same author

Obesity in obstetric anesthesia: A systematic review.

Journal of gynecology obstetrics and human reproduction·2026
Same author

Real-World Efficacy and Drug Survival of Adalimumab in Australian Patients With Psoriasis.

The Australasian journal of dermatology·2026
Same author

Development of an Australasian Dermatology Registry.

The Australasian journal of dermatology·2025
Same author

Intravenous dexmedetomidine use in obstetric anesthesia: a focused review.

International journal of obstetric anesthesia·2025
Same author

Medical care and initial health status of French children returnees from jihadist group operation areas: A cross-sectional study from 2017 to 2020 in one referral French hospital.

Travel medicine and infectious disease·2025

Area of Science:

  • Rheumatology
  • Dermatology
  • Pharmacology

Background:

  • Systemic sclerosis (SSc) is a complex autoimmune disease.
  • The efficacy of D-penicillamine in diffuse cutaneous SSc (dcSSc) remains debated.

Purpose of the Study:

  • To review existing literature on D-penicillamine in dcSSc.
  • To present personal experience with D-penicillamine in dcSSc patients.
  • To evaluate the effectiveness of D-penicillamine in managing skin manifestations of dcSSc.

Main Methods:

  • Comprehensive review of published studies on D-penicillamine for SSc.
  • Analysis of recent clinical experience with D-penicillamine in dcSSc patients.
  • Assessment of treatment outcomes, including skin involvement and recurrence patterns.

Related Experiment Videos

Main Results:

  • D-penicillamine favorably influences the natural course of skin involvement in dcSSc.
  • Low-dose D-penicillamine demonstrates effectiveness in managing skin thickening.
  • Observed recurrence of skin changes upon discontinuation and improvement upon reinitiation supports drug efficacy.

Conclusions:

  • D-penicillamine is effective in altering the natural history of skin disease in early dcSSc.
  • The rheumatologic community should consider D-penicillamine for patients with early dcSSc.
  • Evidence supports the use of D-penicillamine for managing diffuse cutaneous systemic sclerosis skin manifestations.